Management of drug–drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs
Abstract
Over the past 10 years, the number of targeted therapies for haematological malignancies has substantially increased, and many new drugs have entered the market. Many of these therapies have shown improved disease-free survival and reduced toxicity compared with existing treatments, especially in older patients. However, most of these new drugs undergo extensive hepatic metabolism and exhibit moderate to severe drug-drug interactions with triazole antifungal agents, which are essential for the prophylaxis and long-term treatment of invasive fungal infections. In this Review, we give a comprehensive overview of all known drug-drug interactions between new targeted drugs for haematological malignancies and antifungal drugs, in particular the triazoles. We begin with a general background on drug-drug interactions. Next, we provide a management strategy for the use of each targeted haematological drug, and discuss the possible role of therapeutic drug monitoring for both the triazole and the haematological drugs. This Review aims to provide practical guidance to clinical haematologists on managing the complex interplay between targeted therapies for haematological malignancies and triazole antifungal drugs, to pursue better outcomes for their patients.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Drug-drug interactions, especially between the triazoles and other commonly co-administered agents, are increasingly recognized given the complexity of modern patient management.
“Finally, drug-drug interactions, especially between the triazoles and other commonly co-administered agents, are increasingly recognized given the complexity of modern patient management.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [88]
Cites
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200 · see citing works
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169 · see citing works
Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556 · see citing works
Self-citationDurable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML
Dinardo, C. D., Stein, E. M., de Botton, S., Roboz, G. J., Altman, J. K., Mims, A. S., Swords, R. T., Collins, R. H., Mannis, G. N., Pollyea, D. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716984 · Cited by 1,468 · see citing works
Maertens, J. A., Raad, I. I., Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely, O. A., Bow, E. J., Rahav, G., Neofytos, D., Aoun, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01159-9 · Cited by 1,001 · see citing works
Larson, R. A., Druker, B. J., Guilhot, F., O’Brien, S. G., Rivière, G., Krahnke, T., Gathmann, I., & Wang, Y. (2008) · Blood · doi:10.1182/blood-2007-10-116475 · Cited by 644 · see citing works
Picard, S., Titier, K., Étienne, G., Teilhet, E., Ducint, D., Bernard, M., Lassalle, R., Marit, G., Reiffers, J. J., Bégaud, B., et al. (2006) · Blood · doi:10.1182/blood-2006-07-036012 · Cited by 610 · see citing works
Brüggemann, R. J. M., Alffenaar, J. C., Blijlevens, N. M. A., Billaud, E. M., Kosterink, J. G. W., Verweij, P. E., & Burger, D. M. (2009) · Clinical Infectious Diseases · doi:10.1086/598327 · Cited by 458 · see citing works
Self-citationDrug interactions in cancer therapy
Scripture, C. D., & Figg, W. D. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1887 · Cited by 368 · see citing works
Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
Verheijen, R. B., Yu, H., Schellens, J. H. M., Beijnen, J. H., Steeghs, N., & Huitema, A. D. R. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.787 · Cited by 279 · see citing works
Shaw, K. J., & Ibrahim, A. S. (2020) · Journal of Fungi · doi:10.3390/jof6040239 · Cited by 229 · see citing works
Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics
Lathia, C. D., Lettieri, J., Cihon, F., Gallentine, M., Radtke, M., & Sundaresan, P. R. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0068-6 · Cited by 211 · see citing works
Therapeutic drug monitoring of oral targeted antineoplastic drugs
Laughlin, A. M. M., Groenland, S. L., Scherf‐Clavel, O., van Dyk, M., Huisinga, W., Michelet, R., Jaehde, U., Steeghs, N., Huitema, A. D. R., & Kloft, C. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03014-8 · Cited by 201 · see citing works
Levis, M. J., Brown, P. A., Smith, B. D., Stine, A., Pham, R., Stone, R. M., DeAngelo, D. J., Galinsky, I. A., Giles, F., Estey, E. H., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015743 · Cited by 200 · see citing works
Hope on the Horizon: Novel Fungal Treatments in Development
Rauseo, A. M., Coler-Reilly, A. L. G., Larson, L., & Spec, A. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa016 · Cited by 199 · see citing works
Warrilow, A. G. S., Hull, C. M., Parker, J. E., Garvey, E. P., Hoekstra, W. J., Moore, W. R., Schotzinger, R. J., Kelly, D. E., & Kelly, S. L. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03707-14 · Cited by 173 · see citing works
On-target and Off-target-based Toxicologic Effects
Rudmann, D. G. (2012) · Toxicologic Pathology · doi:10.1177/0192623312464311 · Cited by 156 · see citing works
Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects
Dutreix, C., Peng, B., Mehring, G. H., Hayes, M., Capdeville, R., Pokorny, R., & Seiberling, M. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0832-z · Cited by 155 · see citing works
Review of the Novel Investigational Antifungal Olorofim
Wiederhold, N. P. (2020) · Journal of Fungi · doi:10.3390/jof6030122 · Cited by 155 · see citing works
Miura, M. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00103 · Cited by 153 · see citing works
Guilhot, F., Hughes, T. P., Cortes, J. E., Druker, B. J., Baccarani, M., Gathmann, I., Hayes, M., Granvil, C. P., & Wang, Y. L. (2012) · Haematologica · doi:10.3324/haematol.2011.045666 · Cited by 134 · see citing works
Shi, J. G., Chen, X., Emm, T. A., Scherle, P., McGee, R. F., Lo, Y. Y. C., Landman, R. R., McKeever, E., Punwani, N. G., Williams, W. V., et al. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011405663 · Cited by 117 · see citing works
Dürr, P., Schlichtig, K., Kelz, C., Deutsch, B., Maas, R., Eckart, M. J., Wilke, J., Wagner, H., Wolff, K., Preuß, C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03088 · Cited by 111 · see citing works
Lempers, V. J. C., van den Heuvel, J. J. M. W., Rüssel, F. G. M., Aarnoutse, R. E., Burger, D. M., Brüggemann, R. J. M., & Koenderink, J. B. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02931-15 · Cited by 108 · see citing works
Self-citationAgarwal, S. K., Salem, A. H., Danilov, A. V., Hu, B., Puvvada, S. D., Gutierrez, M. E., Chien, D. C., Lewis, L. D., & Wong, S. L. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13175 · Cited by 107 · see citing works
Variability of Sorafenib Toxicity and Exposure over Time: A Pharmacokinetic/Pharmacodynamic Analysis
Boudou, P., Ropert, S., Mir, O., Coriat, R., Billemont, B., Tod, M. M., Cabanes, L., Franck, N., Blanchet, B., & Goldwasser, F. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0439 · Cited by 105 · see citing works
Fontana, L., Perlin, D. S., Zhao, Y., Noble, B. N., Lewis, J. S., Strasfeld, L. M., & Hakki, M. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz282 · Cited by 105 · see citing works
Effect of CYP 3A perpetrators on ibrutinib exposure in healthy participants
de Jong, J., Skee, D. M., Murphy, J., Sukbuntherng, J., Hellemans, P., Smit, J. W., de Vries, R., Jiao, J. J., Snoeys, J., & Mannaert, E. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.156 · Cited by 103 · see citing works
Jones, A. K., Freise, K. J., Agarwal, S. K., Humerickhouse, R. A., Wong, S. L., & Salem, A. H. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9927-9 · Cited by 103 · see citing works
Investigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteers
Dutreix, C., Munarini, F., Lorenzo, S., Roesel, J. L., & Wang, Y. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2287-6 · Cited by 90 · see citing works
Cornely, O. A., Leguay, T., Maertens, J. A., Vehreschild, M. J. G. T., Anagnostopoulos, Α., Castagnola, C., Verga, L., Rieger, C. T., Kondakci, M., Härter, G., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx133 · Cited by 86 · see citing works
Giles, F. J., Yin, O. Q. P., Sallas, W. M., le Coutre, P. D., Woodman, R. C., Ottmann, O. G., Baccarani, M., & Kantarjian, H. M. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1385-4 · Cited by 83 · see citing works
Bose, P., McCue, D. L., Wurster, S., Wiederhold, N. P., Konopleva, M. Y., Kadia, T. M., Borthakur, G. M., Ravandi, F., Masárová, L., Takahashi, K., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa358 · Cited by 80 · see citing works
Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib
Abbas, R., & Hsyu, P. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0391-6 · Cited by 75 · see citing works
Warrilow, A. G. S., Parker, J. E., Price, C. L., Nes, W. D., Garvey, E. P., Hoekstra, W. J., Schotzinger, R. J., Kelly, D. E., & Kelly, S. L. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00349-16 · Cited by 75 · see citing works
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
James, A. J., Smith, C. C., Litzow, M. R., Perl, A. E., Altman, J. K., Shepard, D. R., Kadokura, T., Souda, K., Patton, M., Lu, Z., et al. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00888-w · Cited by 73 · see citing works
Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants
Tanaka, C., Yin, O. Q. P., Smith, T., Sethuraman, V. S., Grouss, K., Galitz, L., Harrell, R. E., & SCHRAN, H. F. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010367428 · Cited by 70 · see citing works
Reda, G., Cassin, R., Dovrtělová, G., Matteo, C., Giannotta, J. A., D’Incalci, M., Cortelezzi, A., & Zucchetti, M. (2019) · Haematologica · doi:10.3324/haematol.2018.213157 · Cited by 68 · see citing works
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia
Rausch, C. R., Dinardo, C. D., Maiti, A., Jammal, N., Kadia, T. M., Marx, K. R., Borthakur, G. M., Savoy, J. M., Pemmaraju, N., DiPippo, A. J., et al. (2021) · Cancer · doi:10.1002/cncr.33508 · Cited by 66 · see citing works
Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects
Narasimhan, N. I., Dorer, D. J., Niland, K., Haluska, F. G., & Sonnichsen, D. S. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.109 · Cited by 60 · see citing works
Principe, M. I. D., Sarmati, L., Cefalo, M., Fontana, C., Santis, G. D., Buccisano, F., Maurillo, L., Bellis, E. D., Postorino, M., Sconocchia, G., et al. (2016) · Mycoses · doi:10.1111/myc.12508 · Cited by 55 · see citing works
Individualised medicine: why we need Bayesian dosing
Donagher, J., Martin, J., & Barras, M. A. (2017) · Internal Medicine Journal · doi:10.1111/imj.13412 · Cited by 54 · see citing works
Effect of Ketoconazole on the Pharmacokinetics of Oral Bosutinib in Healthy Subjects
Abbas, R., Hug, B. A., Leister, C. A., Burns, J., & Sonnichsen, D. S. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010387427 · Cited by 53 · see citing works
de Jong, J., Hellemans, P., Wilde, S. D., Patricia, D., Masterson, T. J., Manikhas, G., Myasnikov, A., Шевкетович, О. Д., Córdoba, R., Panizo, C., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1460474 · Cited by 52 · see citing works
Hsu, L. Y., Lee, D., Yeh, S.-P., Bhurani, D., Khanh, B. Q. K., Low, C. Y., Norasetthada, L., Chan, T. M., Kwong, Y., Vaid, A. K., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.02.019 · Cited by 46 · see citing works
Epstein, D. J., Seo, S. K., Huang, Y.-T., Park, J., Klimek, V. M., Berman, E., Tallman, M. S., Frattini, M. G., & Papanicolaou, G. A. (2018) · Journal of Infection · doi:10.1016/j.jinf.2018.03.015 · Cited by 44 · see citing works
Tapaninen, T., Olkkola, A. M., Tornio, A., Neuvonen, M., Elonen, E., Neuvonen, P. J., Niemi, M., & Backman, J. T. (2019) · Clinical and Translational Science · doi:10.1111/cts.12716 · Cited by 44 · see citing works
Gomes, M. Z. R., Jiang, Y., Mulanovich, V. E., Lewis, R. E., & Kontoyiannis, D. P. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01527-13 · Cited by 41 · see citing works
Self-citationMu, S., Tang, Z., Novotny, W. F., Tawashi, M., Li, T.-K., Ou, Y. C., & Sahasranaman, S. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-04015-w · Cited by 40 · see citing works
Shaik, M. N., LaBadie, R. R., Rudin, D., & Levin, W. J. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2502-0 · Cited by 33 · see citing works
Aslanis, V., Umehara, K., Huth, F., Ouatas, T., Bharathy, S., Butler, A. A., Zhou, W., & Gadbaw, B. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03907-1 · Cited by 33 · see citing works
Shi, J., Fraczkiewicz, G., Williams, W. V., & Yeleswaram, S. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.30 · Cited by 30 · see citing works
Dai, D., Yang, H. Q., Nabhan, S., Liu, H., Hickman, D. K., Liu, G., Zacher, J., Vutikullird, A., Prakash, C., Agresta, S. V., et al. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02673-6 · Cited by 29 · see citing works
Extended Dosing Regimens for Fungal Prophylaxis
Lehrnbecher, T., Bochennek, K., Klingebiel, T. E., Gastine, S., Hempel, G., & Groll, A. H. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00010-19 · Cited by 29 · see citing works
Stanzani, M., Cricca, M., Sassi, C., Sutto, E., Cicco, G. D., Bonifazi, F., Bertuzzi, C., Bacci, F., Paolini, S., Cavo, M., et al. (2019) · Mycoses · doi:10.1111/myc.12978 · Cited by 26 · see citing works
Self-citationPrecision dosing of targeted anticancer drugs—challenges in the real world
Kim, H. Y., Martin, J. H., McLachlan, A. J., & Boddy, A. V. (2017) · Translational Cancer Research · doi:10.21037/tcr.2017.10.30 · Cited by 25 · see citing works
Fundament and Prerequisites for the Application of an Antifungal TDM Service
Brüggemann, R. J. M., & Aarnoutse, R. E. (2015) · Current Fungal Infection Reports · doi:10.1007/s12281-015-0224-3 · Cited by 24 · see citing works
Self-citationAbbas, R., Leister, C. A., Gaaloul, M. E., Chalon, S., & Sonnichsen, D. S. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.07.006 · Cited by 22 · see citing works
Rausch, C. R., Dinardo, C. D., Maiti, A., Jammal, N., Kadia, T. M., Marx, K. R., Borthakur, G. M., Savoy, J. M., Pemmaraju, N., DiPippo, A. J., et al. (2019) · Blood · doi:10.1182/blood-2019-131988 · Cited by 19 · see citing works
Jin, F., Gao, Y., Zhou, H., Fang, L., Li, X., & Ramanathan, S. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2891-8 · Cited by 17 · see citing works
Muilwijk, E. W., Maertens, J. A., van der Velden, W. J. F. M., ter Heine, R., Colbers, A. P. H., Burger, D. M., Andes, D. R., Theunissen, K., Blijlevens, N. M. A., & Brüggemann, R. J. M. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky324 · Cited by 17 · see citing works
Self-citationHsyu, P., Pignataro, D. S., & Matschke, K. T. (2017) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.396 · Cited by 14 · see citing works
Nakahara, R., Sumimoto, T., Ogata, M., Sato, Y., & Itoh, H. (2019) · Clinical Case Reports · doi:10.1002/ccr3.2191 · Cited by 10 · see citing works
Sharma, S., Guo, Y., Jin, F., Li, X., Dubowy, R. L., Newcomb, T. G., & Ramanathan, S. (2015) · Blood · doi:10.1182/blood.v126.23.4172.4172 · Cited by 3 · see citing works
Flagged first, then by citations
2 of the 66 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Synthesis methods of 1,2,3-/1,2,4-triazoles: A review
Dai, J., Tian, S., Yang, X., & Liu, Z. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.891484 · Cited by 143 · see citing works
Epidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109 · see citing works
“88”
New Perspectives on Antimicrobial Agents: Isavuconazole
Lewis, J. S., Wiederhold, N. P., Hakki, M., & Thompson, G. R. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00177-22 · Cited by 94 · see citing works
Stemler, J., de Jonge, N., Skoetz, N., Sinkó, J., Brüggemann, R. J., Busca, A., Ben-Ami, R., Ráčil, Z., Piechotta, V., Lewis, R., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00073-4 · Cited by 69 · see citing works
Self-citationTreatment of Invasive Aspergillosis: How It’s Going, Where It’s Heading
Boyer, J., Feys, S., Zsifkovits, I., Hoenigl, M., & Egger, M. (2023) · Mycopathologia · doi:10.1007/s11046-023-00727-z · Cited by 65 · see citing works
Recommendations on the use of azole antifungals in hematology-oncology patients
Perea, J. R. A., Mensa, J., Barberán, J., Vázquez, L., de Oteyza, J. P., Kwon, M., Yáñez, L., Aguado, J. M., Gracián, A. C., Solano, C., et al. (2023) · Revista Española de Quimioterapia · doi:10.37201/req/013.2023 · Cited by 43 · see citing works
Singh, A., Kaur, K., Kaur, H., Mohana, P., Arora, S., Bedi, N., Chadha, R., & Bedi, P. M. S. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.134456 · Cited by 28 · see citing works
Ghomi, M. K., Noori, M., Montazer, M. N., Zomorodian, K., Dastyafteh, N., Yazdanpanah, S., Sayahi, M. H., Javanshir, S., Nouri, A., Asadi, M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-37203-z · Cited by 28 · see citing works
Andes, D. R., Brüggemann, R. J. M., Flanagan, S., Lepak, A. J., Lewis, R. E., Ong, V. S., Rubino, C. M., & Sandison, T. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae415 · Cited by 26 · see citing works
Self-citationBatista, M. V., Gil, M. P. U., Jiang, Y., Neofytos, D., Cortez, A. C., Feriani, D., Schmidt-Filho, J., Silva, I. L. A. F. E., RAAD, I. I., & Hachem, R. Y. (2023) · Journal of Fungi · doi:10.3390/jof9020166 · Cited by 25 · see citing works
Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations
Flanagan, S., Walker, H., Ong, V. S., & Sandison, T. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.01339-23 · Cited by 25 · see citing works
Inhaled antifungal therapy: benefits, challenges, and clinical applications
Ito, K. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2084530 · Cited by 22 · see citing works
Hu, W., Zhang, W., Zhou, Y., Luo, Y., Sun, X., Xu, H., Shi, S., Li, T., Xu, Y., Yang, Q., et al. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01656 · Cited by 21 · see citing works
Systemic Antifungal Therapy for Invasive Pulmonary Infections
Ben‐Ami, R. (2023) · Journal of Fungi · doi:10.3390/jof9020144 · Cited by 19 · see citing works
Zhang, D., Zhou, N., Yang, L., Yu, Z., Ma, D., Wang, D., Li, Y., Liu, B., Wang, B.-F., Xu, H., et al. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c02981 · Cited by 18 · see citing works
Therapeutic drug monitoring of isavuconazole: Trends and update
Tan, Z., Zhang, N., Liang, B., Bai, N., & Cai, Y. (2025) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2025.107619 · Cited by 17 · see citing works
Clinical Uses of Inhaled Antifungals for Invasive Pulmonary Fungal Disease: Promises and Challenges
Vuong, N. N., Hammond, D. E., & Kontoyiannis, D. P. (2023) · Journal of Fungi · doi:10.3390/jof9040464 · Cited by 16 · see citing works
Gatti, M., & Pea, F. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2274984 · Cited by 16 · see citing works
Liposomal amphotericin B—the future
Hoenigl, M., Lewis, R. E., van de Veerdonk, F. L., Verweij, P. E., & Cornely, O. A. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac353 · Cited by 17 · see citing works
Self-citationDouglas, A. P., Lamoth, F., John, T. M., Groll, A. H., Shigle, T. L., Papanicolaou, G. A., Chemaly, R. F., Carpenter, P. A., Dadwal, S., Walsh, T. J., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.01.892 · Cited by 15 · see citing works
Design, synthesis, evaluation and optimization of novel azole analogues as potent antifungal agents
Zhang, J., Wang, Z., Gai, C., Yang, F., Yun, X., Jiang, B., Zou, Y., Meng, Q., Zhao, Q., & Chai, X. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117543 · Cited by 13 · see citing works
Dinh, A., Savoy, J. M., Kontoyiannis, D. P., Takahashi, K., Issa, G. C., Kantarjian, H. M., Dinardo, C. D., & Rausch, C. R. (2024) · Cancer · doi:10.1002/cncr.35251 · Cited by 12 · see citing works
Zhang, W., Zhang, H., Gao, Y., Lei, J., & Suo, C. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1596688 · Cited by 12 · see citing works
Sepehri, S., & Khedmati, M. (2023) · Archiv der Pharmazie · doi:10.1002/ardp.202300252 · Cited by 11 · see citing works
Xin, H., Tian, J., Deng, T., Zhou, Q., Wang, Y., Fu, H., Pu, H., & Xue, W. (2024) · Molecular Diversity · doi:10.1007/s11030-024-11049-7 · Cited by 10 · see citing works
Enneiymy, M., & Aissouq, A. E. (2025) · Journal of Fluorescence · doi:10.1007/s10895-025-04232-y · Cited by 9 · see citing works
Fungal Influences on Cancer Initiation, Progression, and Response to Treatment
Bilal, H., Khan, M. N., Khan, S., Shafiq, M., Fang, W., Zeng, Y., Guo, Y., Li, X., Zhao, B., Lv, Q., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1609 · Cited by 8 · see citing works
High-Risk Neutropenic Fever and Invasive Fungal Diseases in Patients with Hematological Malignancies
Mori, G., Diotallevi, S., Farina, F., Lolatto, R., Galli, L., Chiurlo, M., Acerbis, A., Xue, E., Clerici, D. T., Mastaglio, S., et al. (2024) · Microorganisms · doi:10.3390/microorganisms12010117 · Cited by 8 · see citing works
Vithlapara, P., Chotaliya, M., Mori, D., & Dudhat, K. R. (2024) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-024-09848-4 · Cited by 6 · see citing works
Chen, L., Li, C., Bai, H., Li, L., & Chen, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.960186 · Cited by 6 · see citing works
Antifungal Prophylaxis in Acute Myeloid Leukemia: New Drugs, New Challenges?
Stemler, J., & Cornely, O. A. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000742 · Cited by 6 · see citing works
Kondža, M., Bukić, J., Ćavar, I., & Tubić, B. (2025) · Drugs and Drug Candidates · doi:10.3390/ddc4020024 · Cited by 5 · see citing works
Cass, L., Ayrton, J., Brüggemann, R. J. M., Moore, J. A., Martin, U. J., Grey, L., Hyman, M., & Berman, L. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf384 · Cited by 5 · see citing works
Self-citationReal world co‐prescribing contraindicated drugs with fluconazole and itraconazole
Je, N. K., Youm, S., & Chun, P. (2023) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5604 · Cited by 5 · see citing works
Clinically relevant bidirectional drug‐drug interaction between midostaurin and voriconazole
Haefliger, D., Marzolini, C., Lamoth, F., Pabst, T., Buclin, T., & Livio, F. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15743 · Cited by 4 · see citing works
IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients
Vallejo, C. T., Jarque, I., Fortün, J., Casado, A., & Pemán, J. (2023) · Journal of Fungi · doi:10.3390/jof9060628 · Cited by 4 · see citing works
Population Pharmacokinetic Models of Venetoclax in Hematologic Malignancies: A Systematic Review
Zhao, Y., Guo, N., Zhu, Y., Shang, J., Chen, J., Luo, X., Liu, Y., Zhang, X., & Huang, L. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s458927 · Cited by 3 · see citing works
Tang, P.-F., Bao, S.-S., Xiao, Z., Xie, W.-F., Wu, X.-M., Ge, H.-L., & Shao, C.-F. (2023) · BMC Chemistry · doi:10.1186/s13065-023-01017-x · Cited by 3 · see citing works
Cattaneo, D., Torre, A., Schiuma, M., Civati, A., Casalini, G., Gori, A., Antinori, S., & Gervasoni, C. (2024) · Journal of Fungi · doi:10.3390/jof10020107 · Cited by 3 · see citing works
Clinical pharmacology and practical aspects of isavuconazole use
Veselov, A. V. (2023) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2023.4.379-394 · Cited by 3 · see citing works
Ding, N., Zhang, J., Yang, D., & Chen, L. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2444579 · Cited by 3 · see citing works
de Kort, E., Buil, J. B., Schalekamp, S., Schaefer‐Prokop, C. M., Verweij, P. E., Schaap, N. P., Blijlevens, N. M. A., & van der Velden, W. J. F. M. (2022) · Journal of Fungi · doi:10.3390/jof8090925 · Cited by 3 · see citing works
Self-citationCattaneo, D., Ridolfo, A. L., Dalu, D., Pruneri, C., Giacomelli, A., Cossu, M. V., Ruggieri, L., Fasola, C., Civati, A., Dolci, A., et al. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2489393 · Cited by 2 · see citing works
Evaluation of the cytochrome P450-mediated drug interaction profile of olorofim
Cornelissen, K., Rex, J. H., Zinzi, D., Law, D., Gill, R. U., Jones, H. M., Maertens, J. A., Chen, S. C.-A., & Brüggemann, R. J. M. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01745-25 · Cited by 2 · see citing works
Self-citationDetermination of Orelabrutinib in Human Plasma Using LC-MS/MS
Zhao, Y., Guo, Y., Chen, X., Yang, Y., Ma, H., Wang, Y., & Sun, L. (2023) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001106 · Cited by 2 · see citing works
Guo, Y., Du, T.-T., Yang, Y., Zhao, Y., Chen, X., Ma, H., Sun, L., & Wang, Y. (2024) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001190 · Cited by 2 · see citing works
Lewis, R. E., & Stanzani, M. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.09.010 · Cited by 1 · see citing works
Self-citationXie, P., Lu, L., Tian, Y., Jia, R., Tian, X., & Bai, P. (2025) · SAGE Open Medicine · doi:10.1177/20503121251328762 · Cited by 1 · see citing works
Myasthenia gravis and community-acquired pneumonia: therapeutic challenges
Chen, X., Ding, J., Zhang, J., Dai, H., & Yu, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1695526 · Cited by 1 · see citing works
Hunter, C. J., Chou, A. D., Roeder, H., Eighmy, W., Bewersdorf, J. P., Mendez, L., Stahl, M. F., Podoltsev, N. A., Zeidan, A. M., & Shallis, R. M. (2025) · Leukemia Research · doi:10.1016/j.leukres.2025.108144 · Cited by 1 · see citing works
Zhao, Y., Ren, X., Chen, J., Zhu, Y., Guo, N., Zhang, X., & Huang, L. (2026) · Medicine · doi:10.1097/md.0000000000047447 · Cited by 1 · see citing works
Zhao, Y., Song, X., Zhang, L., Zhu, Y., Chen, J., Gong, Y., Luo, X., He, H., Zhang, X., & Huang, L. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s583847 · Cited by 1 · see citing works
Ramadthan, E. M., Al-Nama, K. S., & Al-Sabawi, A. H. (2026) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2026.102606 · Cited by 1 · see citing works
Farag, C. M., Mercurio, A. C., Rouf, R., Fried, H., Rudshteyn, M., Sheng, T., Tremblay, D. A., Fuller, R., & Levavi, H. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2724605 · Cited by 1 · see citing works
Effects of three flavonoids on the metabolism of lenvatinib
Yang, J., Chen, J., Li, Q.-Q., Xu, R.-A., & Chen, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1438259 · Cited by 1 · see citing works
Quinet, F., Gilliot, S., Beauvais, D., Vasseur, M., Srour, M., Magro, L., Coiteux, V., Chauvet, P., Yakoub‐Agha, I., Odou, P., et al. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552241297391 · Cited by 1 · see citing works
Antifungal Agents and Their Role in the Management of Pulmonary Aspergillosis
Henig, O., & Ben‐Ami, R. (2024) · Springer eBooks · doi:10.1007/978-3-031-76524-7_8 · Cited by 1 · see citing works
Veringa, A., Brüggemann, R. J. M., & Alffenaar, J. C. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106854
Self-citationAntifungal Prophylaxis in the Era of Targeted Chemotherapy for Acute Myelogenous Leukemia
Lewis, R. E., & Stanzani, M. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00474-0
Self-citationChoudhary, P., & Chhillar, A. K. (2025) · Anti-Infective Agents · doi:10.2174/0122113525358342250120105938
Lu, C., Cheng, D., Xie, Y., Shang, M., Chen, R., Zhu, Y., Gong, J., & Zhou, H. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-00930-2
Liang, B., Li, F., Luan, S., Zhang, N., Zeng, J., Dou, L., & Cai, Y. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf398
Vignal, N., Allard, M., Fodil, S., Lengliné, É., Sauvageon, H., Sébert, M., Plé, A., Réa, D., Mourah, S., & Goldwirt, L. (2025) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001426
Walsh, T. J., Coleman, C. I., Johnson, M. D., Lovelace, B., & Alexander, B. D. (2026) · Mycopathologia · doi:10.1007/s11046-025-01043-4
Vasii, S.-O., Crisan, F. G., Lazăr, S.-M., IONITA, C. O., ILIESCU, D., Ioniță, I., Malita, D. C., Voicu, M., Voicu, A., & Udrescu, L. (2026) · Diagnostics · doi:10.3390/diagnostics16101507
Aspergillus fumigatus as a causative agent of a number of dangerous allergic diseases
Lisiecka, M. Z., & Luczak, J. (2026) · Reviews on Environmental Health · doi:10.1515/reveh-2026-0024
Therapeutic Failure in Invasive Fungal Infections: Beyond Antifungal Resistance—A Narrative Review
Rivas-Pinedo, P., & Oñate, J. (2026) · Journal of Fungi · doi:10.3390/jof12080596
- Authors
- Brüggemann, R. J., Verheggen, R., Boerrigter, E., Stanzani, M., Verweij, P. E., Blijlevens, N. M. A., & Lewis, R. E.
- Affiliations
- Radboud University Medical Center (NL)
- University of Bologna (IT)
- Corresponding author
- Brüggemann, Roger J
- ORCID
- Verweij, Paul E
- Venue
- The Lancet Haematology
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 9
- Issue
- 1
- Pages
- e58-e72
- ISSN
- 2352-3026 (ISSN-L)
- OpenAlex
- W4200115987
- Cited by
- 67
- References
- 66
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 15 · 2023: 19 · 2022: 10
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- The Lancet Haematology (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Keywords
- drug-drug interactions, targeted therapy, hematologic malignancies, triazole antifungals, invasive fungal infections, prophylaxis, hepatic metabolism, therapeutic drug monitoring, management strategies
- MeSH terms
- Aged, Antifungal Agents, Drug Interactions, Pharmaceutical Preparations, Humans, Triazoles, Hematologic Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
